send link to app

MediDrug app for iPhone and iPad


4.2 ( 4112 ratings )
Health & Fitness Medical
Developer: Medilogy srl
Free
Current version: 1.0.1, last update: 7 years ago
First release : 18 Mar 2014
App size: 1.06 Mb

MEDIDRUG is a Medication Decision Support System that provides drug-to-drug and drug-to-substance interaction alerts, dosing guidance, formulary decision support and links to Evidence Based Medicine contents.

Use this app to access your MEDIDRUG subscription on your iPad. If you don’t have one yet, download the app and get a free 30 days trial.

MEDIDRUG is very intuitive, easy to use, fast and effective. It uses colour codes to show the risk factor and provides the best alternatives for the selected substances.

MEDIDRUG is based on Medbase’s drug databases. MedBase is a Finnish company formed by experts in pharmaco-therapeutics, which produces medical databases to health care professionals to safeguard effective and safe clinical use of drugs. In addition to its expertise, Medbase has collaboration with several experts in pharmacotherapy in several countries, including those of Karolinska Institutet in Sweden, which guarantees a high scientific quality and frequent updates.

The MEDIDRUG Knowledge Base is composed by:

SFINX

It is a drug-drug interaction database containing concise and validated information on the consequences of and the recommendations for more than 17.000 pairs. It produces warnings about potential drug interactions and offers medical recommendations on their avoidance and control.

SFINX contains information about relevant pharmacokinetic interactions, that can be supported by scientific literature or by clinical studies referred to in drug SPCs (Summary of the Product Characteristics), and furthermore some clinically important pharmacokinetic interactions, that can be foreseen on the basis of known metabolic pathways. Documented pharmacodynamic interactions are also included.

Interaction texts are based on substance names and, whenever relevant, substance formulations.

PHARAO

(PHARmacological Assessment On-line) is a database containing information on adverse drug effects. In PHARAO the adverse effect profile of more than 1300 drugs has been evaluated with regard to 9 clinically important adverse drug effects:

•Anticholinergic effect
•Risk of bleeding
•Constipation
•Orthostatism
•QT-prolongation
•Renal toxicity
•Sedation
•Risk of seizures
•Serotonergic effect

With PHARAO, the users can check the adverse effect profile of a single drug and perform a drug chart review to analyse the risk profile of patients medication.

RENBASE

It gives concise information in a user-friendly format, on the safety and dosage modifications of different drugs, in patients with renal failure. In addition to clinically used drugs, information exists also on vitamins, micronutrients and special license agents. The goal of Renbase is to provide up-to-date information on drug safety in renal failure, with a powerful search methods that enable quick help for decision making when prescribing or dispensing medications.

RENBASE analyses the pharmacokinetics and safety of various drugs and substances by dividing them into 4 categories, based on the degree of renal failure by glomerular filtration rate (GFR - according to the classification by the European Medicines Agency – EMEA).

GRAVBASE / LACTBASE

It gives concise information on the safety of different drugs during pregnancy and lactation, in a user-friendly format. In addition to clinically used drugs, information are also available on vitamins, illicit substances of abuse and commonly used substances as caffeine, nicotine etc. The goal of Gravbase and Lactbase is to provide the user with an up-to-date information on the safety of various substances during pregnancy and lactation, with powerful search methods that enable quick help for decision making when prescribing or dispensing medications.

GRAVBASE-LACTBASE analyses the safety of various drugs and substances and divides them into 4 categories according to the level of documentation available and according to a risk analysis.